Lantern Pharma Granted Three U.S. FDA Rare Pediatric Disease Designations in Multiple Ultra Rare Children’s Cancers
Lantern Pharma Inc., an AI-driven company focused on developing targeted cancer therapies through its proprietary RADR® AI and machine learning platform, announced today that it has received three Rare Pediatric Disease Designations (RPDD) from the FDA. These designations were granted for malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma, all of which are part of the company's clinical-stage drug programs.
Lantern Pharma Granted Three U.S. FDA Rare Pediatric Disease Designations in Multiple Ultra Rare Children’s Cancers